INDIANAPOLISThe Human Genome Sequencing Center at Baylor College of Medicine boosted its sequencing capabilities with an agreement to acquire seven additional Genome Sequencer FLX Systems from 454 Life Sciences, a Roche company.
With 10 Genome Sequencer FLX Systems, the Human Genome Sequencing Center will be in a unique position to apply 454 Life Sciences technologies to problems ranging from the deciphering of new genomes to the analysis of mutations associated with human diseases.
These instruments previously proved their capabilities in the arena of whole genome sequencing, said Richard Gibbs, Professor and Director of the Human Genome Sequencing Center at Baylor College of Medicine, a former member of the 454 Life Sciences Scientific Advisory Board until March 2007. Now they have demonstrated their potential role in large scale mutation detection.
To better understand genetic basis for disease - including cancer, heart disease, and asthma - genomic information from large numbers of individuals need to be analyzed in a rapid and cost-effective manner. Rapid DNA sequencing technologies allow researchers to identify all genetic changes when comparing healthy individuals to those with disease.
This purchase helps demonstrate that the GS FLX is a proven technology with nearly 100 published peer-review articles, said Lonnie Shoff, Senior Vice President of Molecular Diagnostics and Applied Science for Roche Diagnostics. We see the GS FLX being used in production sequencing due to the systems scalability to support both small and very large projects, along with the instruments durability, which allows it to be run continuously.
These efforts using the Genome Sequencer FLX are further enhanced by a collaboration with the Human Genome Sequencing Center at Baylor College of Medicine and another Roche company, Roche NimbleGen. Preliminary work from the collaboration was reported in Nature Methods this week, and
|Contact: Lori McLaughlin|